Chronic hand eczema (CHE) is characterized by persistent or recurrent inflammatory lesions on the hands and wrists. Ruxolitinib (Janus kinase [JAK]1/JAK2 inhibitor) cream has demonstrated efficacy in atopic and nonatopic hand eczema. In a phase 2 study in adults with moderate-to-severe nonatopic CHE (NCT05906628), 1.5%...
M. Zirwas, R. Chovatiya, Benjamin D. Ehst et al.· SKIN The Journal of Cutaneou...· 0 citations
INTRODUCTION
Atopic dermatitis (AD) is a chronic, burdensome skin condition with significant impact on quality of life. Topical therapies are recommended as first-line treatment; however, patients with moderate-to-severe disease or inadequate disease control may require escalation to systemic therapy. Despite the centr...
P. Lio, Autumn Burnette, Alexa Hetzel et al.· Dermatologic Therapy· 0 citations
Ruxolitinib cream applied as needed over 44 weeks was well tolerated and demonstrated disease control in children aged 2-11 years, consistent with findings in adolescents and adults.
A. Paller, L. Stein Gold, E. Simpson et al.· Journal of American Academy...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.